Response to Medicare’s announcement of Aduhelm price hike.
Secretary of Health and Human Services Xavier Becerra ordered a reassessment of Medicare’s proposed pricing for Aduhelm on Monday. The Alzheimer’s drug had dropped in price due to pressure placed on President Biden’s administration, but Medicare still announced a 14.5% increase in monthly premium, raising the price from $148.50 to $170.10.
“Today I’m instructing the Centers for Medicare and Medicaid Services (CMS) to reassess the recommendation for the 2022 Medicare Part B premium, given the dramatic price change of the Alzheimer’s drug, Aduhelm,” Secretary Becerra stated. “With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation.”
As the Lord Leads, Pray with Us…
- For Secretary Becerra in his goal to make science-backed treatment accessible.
- For President Biden as he pushes to mitigate public access to the experimental drug Aduhelm.
- That scientists would be granted clarity as they continue to research the effects of this potential treatment for Alzheimers.
Sources: The Hill, AP
